Abstract
The optimal treatment strategy in a goiter patient depends—among other factors—on goiter size, the degree of cosmetic or compressive symptoms, the age of the patient, the impact on the upper airways, the wish to maintain normal thyroid function, the ability of the thyroid gland to take up 131I, and the possibility of thyroid malignancy. When treatment is warranted in a patient with benign goiter, the choice usually stands between surgery and 131I-therapy. Focal destructive treatment, by ethanol sclerotherapy or interstitial laser photocoagulation, may be considered in patients with a solitary benign nodule. If thyroid hyperfunction due to nodular autonomy is the dominant problem, life-long anti-thyroid drug treatment may be relevant in elderly individuals. With the advent of recombinant human TSH (rhTSH) stimulation the goiter reduction following 131I-therapy is significantly enhanced and this treatment is of particular benefit, as compared with conventional 131I-therapy, in patients with a low baseline thyroid 131I uptake and a large goiter. If the rhTSH dose does not exceed 0.1 mg the risk of temporary hyperthyroidism and acute thyroid swelling is low. Since patient satisfaction seemingly is not improved by the greater goiter reduction obtained by rhTSH-stimulated 131I-therapy, and permanent hypothyroidism is more frequent, it may be more relevant to reduce the administered radioactivity equivalent to the rhTSH-induced increase in the thyroid 131I uptake. Future large-scale well-controlled studies should explore this strategy, with focus on cost-benefit and quality of life. A major hindrance of widespread and routine use of rhTSH-stimulated 131I-therapy is its present status as an off-label treatment.
Similar content being viewed by others
References
T.H. Brix, K.O. Kyvik, L. Hegedüs, Major role of genes in the etiology of simple goiter in females: a population-based twin study. J. Clin. Endocrinol. Metab. 84, 3071–3075 (1999)
L. Hegedüs, S.J. Bonnema, F.N. Bennedbæk, Management of simple nodular goiter: current status and future perspectives. Endocr. Rev. 24, 102–132 (2003)
P. Vejbjerg, N. Knudsen, H. Perrild et al., Effect of a mandatory iodization program on thyroid gland volume based on individuals’ age, gender, and preceding severity of dietary iodine deficiency: a prospective, population-based study. J. Clin. Endocrinol. Metab. 92, 1397–1401 (2007)
A.E. Jarløv, L. Hegedüs, T. Gjørup, J.E. Hansen, Accuracy of the clinical assessment of thyroid size. Dan. Med. Bull. 38, 87–89 (1991)
G.H. Tan, H. Gharib, C.C. Reading, Solitary thyroid nodule. Comparison between palpation and ultrasonography. Arch. Intern. Med. 155, 2418–2423 (1995)
R. Paschke, L. Hegedus, E. Alexander, R. Valcavi, E. Papini, H. Gharib, Thyroid nodule guidelines: agreement, disagreement and need for future research. Nat. Rev. Endocrinol. 7, 354–361 (2011)
L. Hegedüs, Clinical practice. The thyroid nodule. N. Engl. J. Med. 351, 1764–1771 (2004)
L. Hegedus, S.J. Bonnema, Approach to management of the patient with primary or secondary intrathoracic goiter. J. Clin. Endocrinol. Metab. 95, 5155–5162 (2010)
S.J. Bonnema, P.B. Andersen, D.U. Knudsen, L. Hegedüs, MR imaging of large multinodular goiters: observer agreement on volume versus observer disagreement on dimensions of the involved trachea. AJR Am. J. Roentgenol. 179, 259–266 (2002)
N.J. Gittoes, M.R. Miller, J. Daykin, M.C. Sheppard, J.A. Franklyn, Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement. Br. Med. J. 312, 484 (1996)
P.V. Pradeep, P. Tiwari, A. Mishra et al., Pulmonary function profile in patients with benign goiters without symptoms of respiratory compromise and the early effect of thyroidectomy. J. Postgrad. Med. 54, 98–101 (2008)
S.J. Bonnema, V.E. Nielsen, L. Hegedüs, Long-term effects of radioiodine on thyroid function, size and patient satisfaction in non-toxic diffuse goitre. Eur. J. Endocrinol. 150, 439–445 (2004)
F.N. Bennedbæk, H. Perrild, L. Hegedüs, Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey. Clin. Endocrinol. (Oxf). 50, 357–363 (1999)
F.N. Bennedbæk, L. Hegedüs, Management of the solitary thyroid nodule: results of a North American survey. J. Clin. Endocrinol. Metab. 85, 2493–2498 (2000)
J.P. Walsh, S.A. Ryan, D. Lisewski et al., Differences between endocrinologists and endocrine surgeons in management of the solitary thyroid nodule. Clin. Endocrinol. (Oxf). 66, 844–853 (2007)
S.J. Bonnema, F.N. Bennedbæk, W.M. Wiersinga, L. Hegedüs, Management of the nontoxic multinodular goitre: a European questionnaire study. Clin. Endocrinol. (Oxf). 53, 5–12 (2000)
S.J. Bonnema, F.N. Bennedbaek, P.W. Ladenson, L. Hegedus, Management of the nontoxic multinodular goiter: a North American survey. J. Clin. Endocrinol. Metab. 87, 112–117 (2002)
M.C. Bhagat, S.S. Dhaliwal, S.J. Bonnema, L. Hegedüs, J.P. Walsh, Differences between endocrine surgeons and endocrinologists in the management of non-toxic multinodular goitre. Br. J. Surg. 90, 1103–1112 (2003)
L.A. Diehl, V. Garcia, S.J. Bonnema, L. Hegedüs, C.C. Albino, H. Graf, Management of the nontoxic multinodular goiter in Latin America: comparison with North America and Europe, an electronic survey. J. Clin. Endocrinol. Metab. 90, 117–123 (2005)
F.N. Bennedbæk, S. Karstrup, L. Hegedüs, Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases. Eur. J. Endocrinol. 136, 240–250 (1997)
H. Dossing, F.N. Bennedbaek, L. Hegedus, Long-term outcome following interstitial laser photocoagulation of benign cold thyroid nodules. Eur. J. Endocrinol. 165, 123–128 (2011)
H. Gharib, E. Papini, R. Paschke et al., American association of clinical endocrinologists, Associazione Medici Endocrinologi, and european thyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J. Endocrinol. Invest. 33, 287–291 (2010)
M.F. Wesche, M.M. Tiel-Van Buul, P. Lips, N.J. Smits, W.M. Wiersinga, A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J. Clin. Endocrinol. Metab. 86, 998–1005 (2001)
F.N. Bennedbæk, L.K. Nielsen, L. Hegedüs, Effect of percutaneous ethanol injection therapy versus suppressive doses of L-thyroxine on benign solitary solid cold thyroid nodules: a randomized trial. J. Clin. Endocrinol. Metab. 83, 830–835 (1998)
F. Zelmanovitz, S. Genro, J.L. Gross, Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J. Clin. Endocrinol. Metab. 83, 3881–3885 (1998)
Grussendorf M, Reiners C, Paschke R, Wegscheider K: Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. J Clin Endocrinol Metab doi:10.1210/jc.2011-0356 (2011)
J.B. Stanbury, A.E. Ermans, P. Bourdoux et al., Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 8, 83–100 (1998)
D.P. Livadas, D.A. Koutras, A. Souvatzoglou, C. Beckers, The toxic effect of small iodine supplements in patients with autonomous thyroid nodules. Clin. Endocrinol. (Oxf). 7, 121–127 (1977)
A. Berghout, W.M. Wiersinga, H.A. Drexhage, N.J. Smits, J.L. Touber, Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 336, 193–197 (1990)
M.I. Surks, E. Ortiz, G.H. Daniels et al., Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291, 228–238 (2004)
J.J. Diez, P. Iglesias, An analysis of the natural course of subclinical hyperthyroidism. Am. J. Med. Sci. 337, 225–232 (2009)
S. Fast, S.J. Bonnema, L. Hegedus, The majority of Danish nontoxic goitre patients are ineligible for Levothyroxine suppressive therapy. Clin. Endocrinol. (Oxf). 69, 653–658 (2008)
R.S. Bahn, H.B. Burch, D.S. Cooper et al., Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American thyroid association and American association of clinical endocrinologists. Thyroid 21, 593–646 (2011)
M.A. Walter, M. Briel, M. Christ-Crain et al., Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. Br. Med. J. 334, 514 (2007)
S.J. Bonnema, F.N. Bennedbæk, J. Gram, A. Veje, J. Marving, L. Hegedüs, Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur. J. Endocrinol. 149, 485–492 (2003)
M. Dietlein, K.W. Lauterbach, H. Schicha, Treatment of toxic nodular goitres: comparative costing of radioiodine therapy and surgery. Exp. Clin. Endocrinol. Diabetes 106(Suppl 4), S66–S70 (1998)
L. Hegedüs, B. Nygaard, J.M. Hansen, Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? J. Clin. Endocrinol. Metab. 84, 756–760 (1999)
T. Watt, M. Grønvold, A.K. Rasmussen et al., Quality of life in patients with benign thyroid disorders. A review. Eur. J. Endocrinol. 154, 501–510 (2006)
N.N. al Suliman, N.F. Ryttov, N. Qvist, M. Blichert-Toft, H.P. Graversen, Experience in a specialist thyroid surgery unit: a demographic study, surgical complications, and outcome. Eur. J. Surg. 163, 13–20 (1997)
S.J. Bonnema, H. Bertelsen, J. Mortensen et al., The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J. Clin. Endocrinol. Metab. 84, 3636–3641 (1999)
D.A. Huysmans, A.R. Hermus, F.H. Corstens, J.O. Barentsz, P.W. Kloppenborg, Large, compressive goiters treated with radioiodine. Ann. Intern. Med. 121, 757–762 (1994)
R. Le Moli, M.F. Wesche, M.M. Tiel-Van Buul, W.M. Wiersinga, Determinants of longterm outcome of radioiodine therapy of sporadic non- toxic goitre. Clin. Endocrinol. (Oxf). 50, 783–789 (1999)
B. Nygaard, L. Hegedüs, M. Gervil, H. Hjalgrim, P. Søe-Jensen, J.M. Hansen, Radioiodine treatment of multinodular non-toxic goitre. Br. Med. J. 307, 828–832 (1993)
J. Bachmann, C. Kobe, S. Bor et al., Radioiodine therapy for thyroid volume reduction of large goitres. Nucl. Med. Commun. 30, 466–471 (2009)
S.J. Bonnema, D.U. Knudsen, H. Bertelsen et al., Does radioiodine therapy have an equal effect on substernal and cervical goiter volumes? Evaluation by magnetic resonance imaging. Thyroid 12, 313–317 (2002)
S.J. Bonnema, V.E. Nielsen, H. Boel-Jørgensen et al., Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J. Clin. Endocrinol. Metab. 92, 3424–3428 (2007)
V.E. Nielsen, S.J. Bonnema, H. Boel-Jørgensen, P. Grupe, L. Hegedüs, Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch. Intern. Med. 166, 1476–1482 (2006)
D.A. Huysmans, W.C. Buijs, M.T. van de Ven et al., Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters. J. Nucl. Med. 37, 2072–2079 (1996)
M.S. Torres, L. Ramirez, P.H. Simkin, L.E. Braverman, C.H. Emerson, Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J. Clin. Endocrinol. Metab. 86, 1660–1664 (2001)
D.A. Huysmans, W.A. Nieuwlaat, R.J. Erdtsieck et al., Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J. Clin. Endocrinol. Metab. 85, 3592–3596 (2000)
V.E. Nielsen, S.J. Bonnema, H. Boel-Jørgensen, A. Veje, L. Hegedüs, Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. J. Clin. Endocrinol. Metab. 90, 79–83 (2005)
C.C. Albino, C.O. Mesa Jr., M. Olandoski et al., Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J. Clin. Endocrinol. Metab. 90, 2775–2780 (2005)
L. Braverman, R.T. Kloos, B. Law Jr., M. Kipnes, M. Dionne, J. Magner, Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr. Pract. 14, 832–839 (2008)
S. Fast, V.E. Nielsen, S.J. Bonnema, L. Hegedus, Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur. J. Endocrinol. 160, 517–528 (2009)
W.A. Nieuwlaat, A.R. Hermus, F. Sivro-Prndelj, F.H. Corstens, D.A. Huysmans, Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J. Clin. Endocrinol. Metab. 86, 5330–5336 (2001)
S. Fast, V.E. Nielsen, P. Grupe, S.J. Bonnema, L. Hegedus, Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J. Nucl. Med. 50, 732–737 (2009)
W.A. Nieuwlaat, D.A. Huysmans, H.C. Van Den Bosch et al., Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J. Clin. Endocrinol. Metab. 88, 3121–3129 (2003)
D.S. Duick, H.J. Baskin, Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocr. Prac. 9, 204–209 (2003)
M.N. Silva, I.G. Rubio, R. Romao et al., Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin. Endocrinol. (Oxf). 60, 300–308 (2004)
O. Cohen, J. Ilany, C. Hoffman et al., Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur. J. Endocrinol. 154, 243–252 (2006)
M. Giusti, C. Cappi, B. Santaniello et al., Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter. Minerva Endocrinol. 31, 191–209 (2006)
G.J. Paz-Filho, C.O. Mesa-Junior, M. Olandoski et al., Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Braz. J. Med. Biol. Res. 40, 1661–1670 (2007)
E.R. Cubas, G.J. Paz-Filho, M. Olandoski et al., Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre. Int. J. Clin. Pract. 63, 583–590 (2009)
R. Romao, I.G. Rubio, E.K. Tomimori, R.Y. Camargo, M. Knobel, G. Medeiros-Neto, High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism. Thyroid 19, 945–951 (2009)
Giusti M, Caputo M, Calamia I et al.: Long-term outcome of low-activity radioiodine administration proceeded by adjuvant recombinant human TSH pretreatment in elderly subjects with multinodular goiter. Thyroid Res. 2, 6 (2009)
C.C. Albino, H. Graf, G. Paz-Filho et al., Radioiodine plus recombinant human thyrotropin do not cause acute airway compression and are effective in reducing multinodular goiter. Braz. J. Med. Biol. Res. 43, 303–309 (2010)
S. Fast, L. Hegedus, P. Grupe et al., Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J. Clin. Endocrinol. Metab. 95, 3719–3725 (2010)
C. Ceccarelli, L. Antonangeli, F. Brozzi et al., Radioiodine (131)I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine (131)I activity to be administered in patients with low uptake. Thyroid 21, 759–764 (2011)
M. Dietlein, B. Dederichs, C. Kobe, P. Theissen, M. Schmidt, H. Schicha, Therapy for non-toxic multinodular goiter: radioiodine therapy as attractive alternative to surgery. Nuklearmedizin 45, 21–34 (2006)
G. Medeiros-Neto, S. Marui, M. Knobel, An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter. Endocrine 33, 109–117 (2008)
G.J. Paz-Filho, H. Graf, Recombinant human thyrotropin in the management of thyroid disorders. Expert. Opin. Biol. Ther. 8, 1721–1732 (2008)
S.J. Bonnema, V.E. Nielsen, L. Hegedüs, Radioiodine therapy in non-toxic multinodular goitre. The possibility of effect-amplification with recombinant human TSH (rhTSH). Acta Oncol. 45, 1051–1058 (2006)
V.E. Nielsen, S.J. Bonnema, L. Hegedüs, The effects of recombinant human thyrotropin, in normal subjects and patients with goitre. Clin. Endocrinol. (Oxf). 61, 655–663 (2004)
S.J. Bonnema, V.E. Nielsen, H. Boel-Jorgensen et al., Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. J. Clin. Endocrinol. Metab. 93, 3981–3984 (2008)
S.J. Bonnema, S. Fast, V.E. Nielsen et al., Serum thyroxine and age: rather than thyroid volume and serum TSH: are determinants of the thyroid radioiodine uptake in patients with nodular goiter. J. Endocrinol. Invest. 34, e52–e57 (2011)
W.A. Nieuwlaat, A.R. Hermus, H.A. Ross et al., Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone. J. Nucl. Med. 45, 626–633 (2004)
B. Nygaard, J.H. Knudsen, L. Hegedüs, A. Veje, J.E. Hansen, Thyrotropin receptor antibodies and Graves’ disease, a side-effect of 131I treatment in patients with nontoxic goiter. J. Clin. Endocrinol. Metab. 82, 2926–2930 (1997)
B. Nygaard, J. Faber, L. Hegedüs, Acute changes in thyroid volume and function following 131I therapy of multinodular goitre. Clin. Endocrinol. (Oxf). 41, 715–718 (1994)
S.J. Bonnema, Upper airway obstruction due to goiter: an overlooked problem. J. Postgrad. Med. 54, 82–83 (2008)
B. Nygaard, R.A. Metcalfe, J. Phipps, A.P. Weetman, L. Hegedüs, Graves’ disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter. J. Endocrinol. Invest. 22, 481–485 (1999)
T. Angusti, A. Codegone, R. Pellerito, A. Favero, Thyroid cancer prevalence after radioiodine treatment of hyperthyroidism. J. Nucl. Med. 41, 1006–1009 (2000)
J.A. Franklyn, P. Maisonneuve, M. Sheppard, J. Betteridge, P. Boyle, Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353, 2111–2115 (1999)
J.A. Franklyn, M.C. Sheppard, P. Maisonneuve, Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 294, 71–80 (2005)
P. Hall, G. Berg, G. Bjelkengren et al., Cancer mortality after iodine-131 therapy for hyperthyroidism. Int. J. Cancer 50, 886–890 (1992)
S. Metso, A. Auvinen, H. Huhtala, J. Salmi, H. Oksala, P. Jaatinen, Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 109, 1972–1979 (2007)
E. Ron, M.M. Doody, D.V. Becker et al., Cancer mortality following treatment for adult hyperthyroidism. Cooperative thyrotoxicosis therapy follow-up study group. JAMA 280, 347–355 (1998)
S. Fast, V.E. Nielsen, S.J. Bonnema, L. Hegedus, Dose-dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0.1, 0.3 and 0.9 mg of rhTSH. Clin. Endocrinol. (Oxf). 72, 411–416 (2010)
V.E. Nielsen, S.J. Bonnema, L. Hegedüs, Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. J. Clin. Endocrinol. Metab. 91, 1317–1322 (2006)
H. Graf, S. Fast, F. Pacini et al., Modified-release recombinant human TSH (MRrhTSH) augments the effect of 131I therapy in benign multinodular goiter. Results from a multicenter international, randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 96, 1368–1376 (2011)
M.S. Cardia, I.G. Rubio, G. Medeiros-Neto, Prolonged follow-up of multinodular goitre patients treated with radioiodine preceded or not by human recombinant TSH. Clin. Endocrinol. (Oxf).64, 474 (2006)
Acknowledgments
We would like to thank the Novo Nordic Foundation, The Agnes and Knut Mørk Foundation, The National Thyroid League, The A.P. Møller Relief Foundation, The Institute of Clinical Research (University of Southern Denmark), The Hans Skouby and wife Emma Skouby Foundation, Dagmar Marshall’s Foundation, Oda Pedersens Research Foundation, and King Christian the X’s Foundation for supporting our clinical trials in this field over the last decade. Viveque E. Nielsen is thanked for her role in a number of our rhTSH-studies. This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Conflict of interest
S.J.B. and S.F. have nothing to declare. L.H is an advisory board member and has received consultancy fees from Genzyme Corporation, Cambridge, MA, USA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bonnema, S.J., Fast, S. & Hegedüs, L. Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131I-therapy. Endocrine 40, 344–353 (2011). https://doi.org/10.1007/s12020-011-9542-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-011-9542-6